Latest News

Transurban Group's ( ASX:TCL ) dividend will be increasing from last year's payment of the same period to A$0.34 on...

We feel now is a pretty good time to analyse Bannerman Energy Ltd's ( ASX:BMN ) business as it appears the company may...

Aurubis (XTRA:NDA) has wrapped up FY 2025 with fourth quarter revenue of €4.4 billion alongside EPS of €1.04, setting the tone for a year where profit margins stayed under pressure but remained positive. Over the past six quarters, the company has seen revenue move from €4.2 billion in Q4 2024 to a range between roughly €4.2 billion and €5.0 billion per quarter, while quarterly EPS has swung between €1.04 and €5.87, highlighting how sensitive earnings are to underlying margin shifts. With...

Xenon Pharmaceuticals (XENE) has quietly outperformed the market over the past month, climbing about 15% even as many biotech peers tread water and putting its late stage epilepsy pipeline back in focus for investors. See our latest analysis for Xenon Pharmaceuticals. Zooming out, the stock’s 30 day share price return of about 15% and solid 90 day share price gain suggest momentum is rebuilding after a more muted 4.42% one year total shareholder return. If Xenon’s move has you rethinking your...

Atai Beckley (ATAI) has quietly turned heads with a sharp year to date rebound, even as recent month and past 3 months returns cooled. Investors are asking whether this reset offers a fresh entry point. See our latest analysis for Atai Beckley. The latest 1 day share price return of 8.37 percent and 7 day gain of 17.33 percent come after a choppy stretch, with a 30 day share price return of negative 16.67 percent and a still impressive 175 percent year to date share price return, alongside a...

Walmart (WMT) just posted its Q3 2026 numbers, with revenue of about $179.5 billion and net income of roughly $6.1 billion translating to EPS of $0.77 as investors focus on how these figures feed into the retailer’s earnings momentum story. The company has seen revenue move from around $169.6 billion in Q3 2025 to $179.5 billion in Q3 2026, while trailing twelve month net income climbed from about $19.4 billion to $22.9 billion. This sets the stage for investors to parse how sustained...

CBRE Group (CBRE) is back in the spotlight after Barclays initiated coverage with an Overweight rating, just as the company doubles down on strategic growth through its Pearce Services acquisition and fresh debt financing. See our latest analysis for CBRE Group. Despite a softer 1 day and recent 7 day share price return, CBRE’s roughly 24 percent year to date share price gain and triple digit multi year total shareholder returns suggest momentum is still very much intact as these strategic...

If you are wondering whether Ares Management is still worth buying after its big multi year run, or if the easy money has already been made, this breakdown will help you consider whether the current price still stacks up to the fundamentals. The stock just closed at $163.07, up 5.5% over the last week and 6.6% over the last month, even though it is still down 8.8% year to date and 5.5% over the past year after a 153.6% 3 year and 291.3% 5 year rally. Behind those moves, investors have been...

Ecolab (ECL) shares have been quietly recalibrating after a choppy few weeks, and that drift gives us a cleaner look at what you are really paying for in this steady compounder. See our latest analysis for Ecolab. At around $264 per share, Ecolab has given investors a solid year to date with a mid teens share price return, while the more modest 1 year total shareholder return hints that momentum has cooled a little after a strong multi year run. If Ecolab’s steady compounding appeals to you,...

Gorilla Technology Group (GRRR) just kicked off a new chapter for its SPAC-era investors by issuing a CVR Payment Notice that lets qualifying CVR holders claim forfeited ordinary shares now reclassified as Price Protection Shares. See our latest analysis for Gorilla Technology Group. The CVR announcement lands after a volatile spell for Gorilla, with a 10.8% 1 day share price return and 19.3% 7 day share price return contrasting sharply with a weak year to date share price return. At the same...

AnaptysBio (ANAB) just turned its long running Jemperli partnership with Tesaro and GSK into a full blown legal battle, and that tug of war over royalties and rights is exactly what the stock is now trading on. See our latest analysis for AnaptysBio. The lawsuit has lit a fire under the stock, with a 1 month share price return of 24.64% and a year to date share price return of 224.10%, signaling powerful, litigation driven momentum, even though the 1 year total shareholder return of 83.01%...

Nutanix (NTNX) just delivered a classic mixed quarter, hitting earnings but falling short on revenue and trimming its full year outlook, and that combination has clearly pressured sentiment around the stock. See our latest analysis for Nutanix. The stock is clearly feeling that tension, with a roughly 32 percent 1 month share price return decline and the latest earnings driven reset weighing on what had been a solid multi year total shareholder return profile. If this quarter has you...

In early December 2025, Emerson and Armexa announced a collaboration to provide DeltaV automation platform users with a global suite of operational technology cybersecurity services, including assessments, network intrusion detection deployments, and OT security for capital projects aligned with ISA/IEC 62443 standards. This move highlights how Emerson is broadening its automation offering into lifecycle OT cybersecurity, aiming to simplify vendor management and strengthen resilience for...

Wondering if CenterPoint Energy at around $38.54 is still worth buying after its strong run, or if most of the upside is already priced in? You are in the right place if you are trying to separate solid value from simple momentum. The stock is down about 3.5% over the last week and roughly flat over the past month, but it is still up 22.4% year to date and 23.4% over the last year, with a 5 year gain of just over 100.2%. That mix of near term softness and long term strength is exactly what...

Investor chatter around Vital Farms (VITL) has picked up as coverage of its lower P/E ratio versus peers intensifies. This has prompted a closer look at whether the recent share pullback signals opportunity or slower growth ahead. See our latest analysis for Vital Farms. Despite the recent pullback, with a 30 day share price return of minus 15.8 percent and a year to date share price return of minus 19 percent, Vital Farms still boasts a strong three year total shareholder return of about 99...

Celsius Holdings recently reported a past quarter with very large year-on-year revenue growth to record sales of US$721 million, expanding its energy drink market share at home and abroad through PepsiCo-backed distribution and new entries into markets such as the U.K., France, Australia and New Zealand. At the same time, the acquisitions of Alani Nu and Rockstar have increased integration complexity and costs, raising questions about whether the company can protect margins while absorbing...

Wondering if Iron Mountain is still worth digging into after its big run over the past few years, or if the value story has already played out? Here is a breakdown of whether the current price really matches the long term fundamentals. After a 249.9% gain over 5 years and 73.3% over 3 years, the stock has cooled off with a 17.7% drop over the last 30 days and is now down 18.8% year to date and 25.9% over the past year, including a 1.4% decline in just the last week. That pullback has come as...

NANO Nuclear Energy (NNE) just signed a feasibility study deal with BaRupOn to explore deploying multiple KRONOS MMR units, targeting up to 1 GW of nuclear power for the massive LAMP innovation hub in Liberty, Texas. See our latest analysis for NANO Nuclear Energy. The BaRupOn feasibility study lands while NANO Nuclear Energy’s share price has been volatile, with a 1 day share price return of 7.91 percent and a 30 day share price return of negative 15.87 percent, but year to date momentum...

The latest move from MannKind (MNKD) is the FDA accepting its supplemental filing for the FUROSCIX ReadyFlow Autoinjector, a potential at home alternative for rapid furosemide delivery in heart and kidney patients. See our latest analysis for MannKind. The FUROSCIX ReadyFlow update lands while MannKind’s share price sits at $5.71, with a 7-day share price return of 6.13 percent but a weaker year-to-date share price return of negative 13.48 percent. However, the 5-year total shareholder return...

Black Diamond Therapeutics recently reported topline Phase 2 data for silevertinib in first-line non-small cell lung cancer patients with non-classical EGFR mutations, and outlined plans to start a randomized Phase 2 trial in newly diagnosed glioblastoma in 2026. The early results, including strong central nervous system response rates and a broad range of EGFR alterations targeted, underscore silevertinib’s potential as a brain-penetrant precision therapy across multiple tumor types. We’ll...

Henry Schein (HSIC) just widened its footprint in preventive dentistry, securing exclusive U.S. distribution rights for vVARDIS Curodont Repair Fluoride Plus across all dental segments starting January 1, 2026. See our latest analysis for Henry Schein. The deal lands while Henry Schein’s 90 day share price return of 5.63 percent and year to date share price return of 6.99 percent point to gradually improving momentum, even though the 3 year total shareholder return of negative 9.81 percent...

If you are wondering whether Madrigal Pharmaceuticals is still worth a look after its huge run-up, or if the smart money has already moved on, this breakdown is for you. The stock has surged an eye-catching 798.5% over the last 3 years and is still up 86.8% year to date, even after a recent 2.5% dip over the past week. Those moves have been driven by growing optimism around Madrigal's lead NASH therapy, which recently gained more attention as investors reassessed the commercial potential of...

If you are wondering whether UL Solutions at around $76.74 is still worth buying after its run this year, you are not alone. This article will break down what that price actually implies about future expectations. The stock has pulled back sharply in the short term, with a 14.9% drop over the last week and an 11.8% slide over the past month, even though it is still up 54.6% year to date and 44.2% over the last year. Recently, investors have been reacting to a mix of headlines around demand...

Aduro Clean Technologies (CNSX:ACT) just signed a multi year collaboration with Mexican environmental association ECOCE to test its Hydrochemolytic Technology on difficult mixed plastic waste, a move that could reshape its commercial pipeline in Latin America. See our latest analysis for Aduro Clean Technologies. That backdrop helps explain why the stock’s momentum has accelerated, with a roughly 32 percent 3 month share price return, a 119 percent year to date share price return, and a...